



Emerging Treatment Options to Fight Malaria: New Compounds and Drug Combinations

Guest Editors:

Dr. Nicolò Musso

Bio-Nanotech Research and
Innovation Tower (BRIT),
University of Catania, 95125
Catania, Italy

Dr. Andrea Marino

Department of Clinical and
Experimental Medicine,
University of Catania, Catania,
Italy

Deadline for manuscript
submissions:

closed (28 September 2023)

Message from the Guest Editors

Over the last few years, renewed attempts to control the disease have reduced the prevalence of malaria by over 50%, raising the prospect that elimination and perhaps eradication may be a long-term possibility.

Achievement of this goal requires the development of new tools, including efficacious vaccines as well as a precise understanding of the pathophysiology and biology of the parasite, and especially novel antimalarial drugs and combinations which could safely ensure the rapid clearance of infection as well as a durable cure without recurrence. In addition, the development of resistance to past and present anti-malarial drugs, especially artemisinin-based regimes, highlights the need for continued research to stay one step ahead, specifically to treat severe complications such as cerebral malaria.

This Special Issue aims to collect original articles, literature reviews, and case reports/case series on emerging treatment options against malaria, with particular interest on new compounds, either experimental or under research, and drug combinations.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Hinh Ly

Department of Veterinary &
Biomedical Sciences, University
of Minnesota, Twin Cities, MN,
USA

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)